Alkylresorcinols as a New Type of Gut Microbiota Regulators Influencing Immune Therapy Efficiency in Lung Cancer Treatment

Table 2

Characteristics of groups of germ-free mice and donors of stool samples for faecal microbiota transplantation.

Group of animals	Number of animals	Material for transplantation	Route of administration	Donor of microbiota
1 (control)	10	0.9% NaCl solution	Intragastric	N/A
2	10	Faecal microbiota sample from donor 1	Intragastric	Donor 1: female, 48 yo; lung adenocarcinoma T4N1M1a, stIV; PFS, 49 months after the ICI therapy
3	10	Faecal microbiota sample from donor 2	Intragastric	Donor 2: male, 71 yo; lung adenocarcinoma T2bN3M1b, stIV; PFS, 5 months after the ICI therapy
4	10	Faecal microbiota sample from donor 3	Intragastric	Donor 3: male, 73 yo; lung adenocarcinoma T2bN0M1, stIV; PFS, 7 months after the ICI therapy

ICIs: immune checkpoint inhibitors; PFS: progression-free survival; N/A: not applicable; yo: years old.